Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib

CONTEXT: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. OBJECTIVE: The objective of the study was to determine the efficacy of salvage therapy after first...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dadu, Ramona, Devine, Catherine, Hernandez, Mike, Waguespack, Steven G., Busaidy, Naifa L., Hu, Mimi I., Jimenez, Camilo, Habra, Mouhammad A., Sellin, Rena V., Ying, Anita K., Cote, Gilbert J., Sherman, Steven I., Cabanillas, Maria E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Endocrine Society 2014
Soggetti:
Endocrine Care
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037722/
https://ncbi.nlm.nih.gov/pubmed/24628550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3588
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi